Protocol Ledger

NCT06504147 · Phase II · RECRUITING

A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Sur

Interventional Phase II clinical trial protocol NCT06504147 sponsored by Oncoinvent Solutions AS in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-15 Enrollment: 114 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06504147
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)114 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06504147
Protocol FieldVerified Registry Value
NCT IdentifierNCT06504147
Consolidated Lead SponsorOncoinvent Solutions AS
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment114 participants (ESTIMATED)
Registered Start Date2024-06-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06504147
Hospital Research SiteLocationSite Profile
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->
Clinica Universidad de NavarraPamplona, SpainOpen Hospital Dossier ->
Hospital Universitari I Politècnic La FeValencia, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI